News for RCUS Stock

Initial Data from the ARC-20 Study of Casdatifan Plus Cabozantinib Showed Nearly Half of Patients with Metastatic Kidney Cancer Had a Confirmed Response Arcus Biosciences Announces New Employment Inducement Grants Arcus Biosciences Announces New Employment Inducement Grants Arcus Biosciences Reports First-Quarter 2025 Financial Results and Provides a Pipeline Update Arcus Biosciences Announces New Employment Inducement Grants Arcus Biosciences to Present First Combination Data for HIF-2a Inhibitor Casdatifan Plus Cabozantinib in an Oral Presentation at the 2025 ASCO Annual Meeting Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2025 Financial Results and Pipeline Update Arcus Biosciences Announces New Employment Inducement Grants Arcus Biosciences Announces New Employment Inducement Grants Arcus Biosciences to Participate in Two Upcoming Investor Conferences Arcus Biosciences Reports Fourth-Quarter and Full-Year 2024 Financial Results and Provides a Pipeline Update Arcus Biosciences Announces New Employment Inducement Grants Arcus Biosciences Retains Rights to Casdatifan, a Potential Best-in-Class HIF-2a Inhibitor, and Announces Pricing of $150 Million Common Stock Offering Arcus Biosciences, Inc. Announces Underwritten Offering of Common Stock New Data Demonstrated Best-in-Class Potential for Casdatifan, a HIF-2a Inhibitor, in Patients with Metastatic Kidney Cancer Arcus Biosciences Announces New Employment Inducement Grants Arcus Biosciences to Present New Data from Casdatifan, a HIF-2a Inhibitor, in an Oral Presentation at the 2025 ASCO GU Symposium Arcus Biosciences Announces New Employment Inducement Grants Arcus Biosciences Appoints Richard Markus, M.D., Ph.D. as Chief Medical Officer Arcus Biosciences Announces New Employment Inducement Grants Arcus Biosciences to Participate in the 43rd Annual J.P. Morgan Healthcare Conference Arcus Biosciences Announces New Employment Inducement Grants Arcus Biosciences Announces New Employment Inducement Grants Arcus Biosciences to Participate in Two Upcoming Investor Conferences Arcus Biosciences Announces New Employment Inducement Grants Arcus Biosciences Reports Third-Quarter 2024 Financial Results and Provides a Pipeline Update Arcus Biosciences Announces that Domvanalimab Plus Zimberelimab Improved Overall Survival in ARC-10, a Randomized Study in Patients with PD-L1-High Non-Small Cell Lung Cancer Arcus Biosciences to Present New Data for Anti-TIGIT Domvanalimab Plus Zimberelimab at the Society for Immunotherapy of Cancer Annual Meeting Arcus Biosciences Announces New Employment Inducement Grants First Clinical Data for Arcus Biosciences’ HIF-2a Inhibitor, Casdatifan, Showed Promising Clinical Activity and Tumor Shrinkage in Patients with Metastatic Kidney Cancer Arcus Biosciences to Host Conference Call to Discuss Third-Quarter 2024 Financial Results and Pipeline Update Arcus Biosciences Announces New Employment Inducement Grants Arcus Biosciences to Present First Clinical Data from ARC-20 Study at the 2024 EORTC-NCI-AACR Symposium Arcus Biosciences Announces Clinical Trial Collaboration Agreement to Evaluate Casdatifan in Combination with Volrustomig in Renal Cell Carcinoma Arcus Biosciences Announces New Employment Inducement Grants Arcus Biosciences Announces New Employment Inducement Grants Arcus Biosciences Secures Up to $250 Million Term Loan Facility from Hercules Capital Arcus Biosciences Announces New Employment Inducement Grants Arcus Biosciences to Participate in Two Upcoming Investor Conferences Arcus Biosciences Reports Second-Quarter 2024 Financial Results and Provides a Pipeline Update Arcus Biosciences to Host Conference Call to Discuss Second-Quarter 2024 Financial Results and Pipeline Update Arcus Biosciences Announces New Employment Inducement Grants Taiho Pharmaceutical Exercises Option for an Exclusive License to Quemliclustat in Japan and Certain Territories in Asia Arcus Biosciences Announces New Employment Inducement Grants Arcus Biosciences Announces New Employment Inducement Grants Arcus Biosciences Completes Patient Enrollment in Phase 3 Trial Evaluating a Domvanalimab-Containing Regimen in First-Line Metastatic Upper GI Cancers Arcus Biosciences to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI Cancers Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI Cancers Arcus Biosciences Announces New Employment Inducement Grants Arcus Biosciences Announces New Employment Inducement Grants Arcus Biosciences Reports First-Quarter 2024 Financial Results and Provides a Pipeline Update Arcus Biosciences to Participate in the Bank of America Healthcare Conference 2024 Arcus Biosciences to Present New Data from Phase 2 Studies of Novel Immuno-Oncology Combinations at the 2024 ASCO Annual Meeting Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2024 Financial Results and Pipeline Update Arcus Biosciences Announces New Employment Inducement Grants Arcus Biosciences Announces New Employment Inducement Grants Arcus Biosciences Announces New Employment Inducement Grants Arcus Biosciences to Participate in Two Upcoming Investor Conferences Arcus Biosciences Announces New Employment Inducement Grants Arcus Biosciences Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides a Pipeline Update Arcus Biosciences Announces New Employment Inducement Grants Arcus Biosciences to Host Conference Call to Discuss Fourth-Quarter and Full-Year 2023 Financial Results and Pipeline Updates Gilead and Arcus Announce Amended Collaboration and Equity Investment Gilead and Arcus Announce Amended Collaboration and Equity Investment Arcus Biosciences Announces New Employment Inducement Grants Data from a Phase 1b Study of Quemliclustat-Based Regimens Showed Promising Overall Survival in Treatment-Naïve Metastatic Pancreatic Cancer Arcus Biosciences Announces New Employment Inducement Grants Exelixis and Arcus Biosciences Announce Clinical Trial Collaboration to Evaluate Zanzalintinib in Combination with AB521 in Patients with Advanced Renal Cell Carcinoma Exelixis and Arcus Biosciences Announce Clinical Trial Collaboration to Evaluate Zanzalintinib in Combination with AB521 in Patients with Advanced Renal Cell Carcinoma Arcus Biosciences Announces New Employment Inducement Grants Arcus Biosciences to Participate in the 6th Annual Evercore ISI HealthCONx Conference Arcus Biosciences Announces New Employment Inducement Grants Arcus Biosciences Reports Third Quarter 2023 Financial Results and Provides a Pipeline Update Gilead and Arcus Announce New Data Showing Encouraging Clinical Activity of Anti-TIGIT Domvanalimab-Containing Regimen as First-Line Treatment for Upper GI Cancers Gilead and Arcus Announce New Data Showing Encouraging Clinical Activity of Anti-TIGIT Domvanalimab-Containing Regimen as First-line Treatment for Upper GI Cancers Arcus Biosciences Announces New Employment Inducement Grants Arcus Biosciences to Present Data from Ongoing EDGE-Gastric Study at ASCO Plenary and to Report Third-Quarter Financial Results on November 7 Arcus Biosciences Announces New Employment Inducement Grants Arcus Biosciences Announces New Employment Inducement Grants Arcus Biosciences Announces New Employment Inducement Grants Arcus Biosciences Announces New Employment Inducement Grants Arcus Biosciences to Participate in Multiple Upcoming Investor Conferences Arcus Biosciences Announces New Employment Inducement Grants Arcus Biosciences Reports Second-Quarter 2023 Financial Results and Provides a Pipeline Update Arcus Biosciences Announces New Employment Inducement Grants Arcus Biosciences Announces New Employment Inducement Grants Arcus Biosciences Announces New Employment Inducement Grants Arcus Biosciences Announces New Employment Inducement Grants Gilead and Arcus Announce Anti-TIGIT Domvanalimab Continues to Demonstrate Consistent Improvement in Progression-Free Survival in Non-Small Cell Lung Cancer Study Gilead and Arcus Announce Anti-TIGIT Domvanalimab Continues to Demonstrate Consistent Improvement in Progression-Free Survival in Non-Small Cell Lung Cancer Study Arcus Biosciences to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference Arcus Biosciences Announces New Employment Inducement Grants Presentations at the 2023 ASCO Annual Meeting Highlight Arcus Biosciences’ Expanding Portfolio of Investigational Medicines and Late-Stage Studies Across Multiple Types of Cancer Gilead Sciences and Arcus Biosciences Expand Partnership to Include Research Programs in Inflammation Gilead Sciences and Arcus Biosciences Expand Partnership to Include Research Programs in Inflammation Arcus Biosciences Reports First Quarter 2023 Financial Results and Provides a Pipeline Update Arcus Biosciences Announces New Employment Inducement Grants Arcus Biosciences Announces New Employment Inducement Grants Arcus Biosciences Announces New Employment Inducement Grants Arcus Biosciences Announces New Employment Inducement Grants Arcus Biosciences to Participate in the Barclays Global Healthcare Conference Arcus Biosciences Reports Fourth-Quarter and Full-Year 2022 Financial Results and Provides a Pipeline Update Arcus Biosciences Announces New Employment Inducement Grants Arcus Biosciences Announces New Employment Inducement Grants Arcus Biosciences to Participate at Upcoming Virtual Investor Events Arcus Biosciences Announces New Employment Inducement Grants Anti-TIGIT Domvanalimab-Containing Study Arms Improve Progression-Free Survival Compared to Anti-PD1 Alone in Phase 2 Non-Small Cell Lung Cancer Study Anti-TIGIT Domvanalimab-Containing Study Arms Improve Progression-Free Survival Compared to Anti-PD1 Alone in Phase 2 Non-Small Cell Lung Cancer Study Arcus Biosciences Announces New Employment Inducement Grants Gilead and Arcus Biosciences Announce Positive Update on Joint TIGIT Program From Interim Analysis of ARC-7 Study in Non-small Cell Lung Cancer Gilead and Arcus Biosciences Announce Positive Update on Joint TIGIT Program From Interim Analysis of ARC-7 Study in Non-Small Cell Lung Cancer Arcus Biosciences to Participate in the 5th Annual Evercore ISI HealthCONx Conference Arcus Biosciences Announces New Employment Inducement Grants Arcus Biosciences Reports Third Quarter 2022 Financial Results and Provides a Pipeline Update Arcus Biosciences Announces New Employment Inducement Grants Arcus Biosciences Announces New Employment Inducement Grants Arcus Biosciences to Participate in Two Upcoming Investor Conferences Arcus Biosciences Announces New Employment Inducement Grants Arcus Biosciences Appoints Dimitry Nuyten, M.D., Ph.D. as Chief Medical Officer Arcus Biosciences Reports Second Quarter 2022 Financial Results and Provides a Pipeline Update Arcus Biosciences to Participate in the 13th Annual Wedbush PacGrow Healthcare Conference Arcus Biosciences Announces New Employment Inducement Grants Arcus Biosciences Announces New Employment Inducement Grants Arcus Biosciences Announces New Employment Inducement Grants Arcus Biosciences Announces New Employment Inducement Grants Arcus Biosciences to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference Arcus Biosciences Announces New Employment Inducement Grants Arcus Biosciences Announces New Employment Inducement Grants Arcus Biosciences Reports First Quarter 2022 Financial Results and Provides a Pipeline Update, Including from the Third Interim Analysis for the ARC-7 Study Arcus Biosciences to Report First Quarter 2022 Financial Results and Pipeline Update Arcus Biosciences Announces New Employment Inducement Grants Arcus Biosciences Announces New Employment Inducement Grants Arcus Biosciences Announces New Employment Inducement Grants Arcus Biosciences Announces New Employment Inducement Grants Arcus Biosciences Presents Data from its Pipeline at Multiple Scientific Conferences Arcus Biosciences Announces New Employment Inducement Grants Arcus Biosciences Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update Arcus Biosciences to Participate in the Upcoming Investor Conferences Arcus Biosciences Announces New Employment Inducement Grants Arcus Biosciences Announces New Employment Inducement Grants Arcus Biosciences Announces New Employment Inducement Grants Arcus Biosciences Provides Update on Clinical Programs, Including Key 2022 Milestones Arcus Biosciences Announces New Employment Inducement Grants Gilead and Arcus Biosciences Complete Closing of Option Exercise for Three Clinical-Stage Programs and New Research Collaboration Gilead and Arcus Biosciences Complete Closing of Option Exercise for Three Clinical-stage Programs and New Research Collaboration Arcus Biosciences Announces New Employment Inducement Grants Taiho Pharmaceutical Exercises Option for an Exclusive License to Arcus Biosciences’ Anti-TIGIT Program in Japan and Certain Territories in Asia Arcus Biosciences Announces New Employment Inducement Grants Arcus Biosciences to Participate in the Upcoming Evercore ISI HealthCONx 2021 Conference Gilead Exercises Options to Three Arcus Biosciences Clinical-stage Programs and Adds Research Collaboration Gilead Exercises Options to Three Arcus Biosciences Clinical-Stage Programs and Adds Research Collaboration Arcus Biosciences Announces New Employment Inducement Grants Arcus Biosciences Reports Third Quarter 2021 Financial Results and Provides an Update on our anti-TIGIT Domvanalimab Arcus Biosciences to Report Third Quarter 2021 Financial Results & Recent Corporate Highlights Arcus Biosciences Announces New Employment Inducement Grants Arcus Biosciences Announces New Employment Inducement Grants Arcus Biosciences Announces New Employment Inducement Grants Arcus Biosciences Announces New Employment Inducement Grants Arcus Biosciences to Participate at Upcoming Investor Conferences Arcus Biosciences Announces New Employment Inducement Grants Arcus Biosciences Announces New Employment Inducement Grants Arcus Biosciences Reports Second Quarter 2021 Financial Results and Provides Operational Highlights Arcus Biosciences to Participate at the 2021 Wedbush PacGrow Virtual Healthcare Conference Arcus Biosciences to Report Second Quarter 2021 Financial Results & Recent Corporate Highlights Arcus Biosciences Announces New Employment Inducement Grants Arcus Biosciences Announces New Employment Inducement Grants Arcus Biosciences Announces New Employment Inducement Grants Anti-TIGIT Domvanalimab-Based Combinations Showed Encouraging Clinical Activity in People with Metastatic, PDL1-High Non-Small Cell Lung Cancer at First Interim Analysis of Arcus Biosciences’ Randomized Phase 2 ARC-7 Study Arcus Biosciences Announces New Employment Inducement Grants Arcus Biosciences Announces New Employment Inducement Grants Arcus Biosciences Presents Early Data from ARC-6, a Phase 1b/2 Study Evaluating Etrumadenant-Based Combinations in Metastatic Castrate-Resistant Prostate Cancer at the 2021 ASCO Annual Meeting Arcus Biosciences Announces New Employment Inducement Grants Arcus Biosciences Reports First Quarter 2021 Financial Results and Provides Operational Highlights Arcus Biosciences Announces New Employment Inducement Grants Arcus Biosciences Presents Updated Data for Etrumadenant in Third-Line Metastatic Colorectal Cancer and New Data on its HIF-2α Program at the AACR 2021 Annual Meeting Arcus Biosciences Announces New Employment Inducement Grants Arcus Biosciences Announces New Employment Inducement Grants Arcus Biosciences Announces New Employment Inducement Grants Arcus Biosciences Announces New Employment Inducement Grants Arcus Biosciences Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Operational Highlights Arcus Biosciences to Participate in Upcoming Investor Conferences Arcus Biosciences Announces New Employment Inducement Grants Gilead Sciences to Increase Its Ownership In Arcus Biosciences Arcus Biosciences Announces New Employment Inducement Grants Arcus Biosciences Presents Promising Initial Data from Phase 1 Portion of ARC-8 Study for AB680 in Metastatic Pancreatic Cancer Arcus Biosciences Announces New Employment Inducement Grants Arcus Biosciences to Present Preliminary Data from Phase 1 Portion of ARC-8 Study for AB680 in Metastatic Pancreatic Cancer at ASCO-GI Symposium Arcus Biosciences Appoints Biotech Industry Veteran, Andrew Perlman, M.D., Ph.D. and Gilead’s SVP of Research Biology, Michael Quigley, Ph.D. to Its Board of Directors Arcus Biosciences Announces New Employment Inducement Grants Arcus Biosciences Expands Strategic Relationship with WuXi Biologics to Develop a Best-in-Class anti-CD39 Antibody for the Treatment of Cancer Arcus Biosciences to Participate in the Evercore ISI 3rd Annual HealthCONx Virtual Conference Arcus Biosciences Announces New Employment Inducement Grants Arcus Biosciences Announces Third Quarter 2020 Financial Results and Corporate Updates Arcus to Collaborate With AstraZeneca on Registrational Trial for Domvanalimab, Arcus’s Novel Anti-TIGIT Antibody, Plus Imfinzi® in Stage III NSCLC Arcus Biosciences Announces New Employment Inducement Grants Jennifer Jarrett Returns to Arcus Biosciences as Chief Operating Officer